Business Wire

Yamaha Motor: Consolidated Business Results Summary ‐ Full Fiscal Year Ending December 31, 2024

13.2.2025 03:00:00 EET | Business Wire | Press release

Share

Yamaha Motor Co., Ltd. (Tokyo: 7272) announces its consolidated business results for the full 2024 fiscal year.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250212964437/en/

Yamaha Motor Headquarters, Iwata, Shizuoka, Japan (Photo: Business Wire)

Revenues were 2,576.2 billion yen (an increase of 161.4 billion yen or 6.7% compared with the previous fiscal year) due to more unit sales and higher prices per unit for models sold in Brazil and India in our core business of motorcycles.

As for operating income, after recording the effects soaring prices had on raising labor costs and other SG&A expenses; expenses linked to conducting reviews of our business structure, such as inventory valuation reductions; and impairment losses on certain fixed assets in the SPV and RV businesses; the final figure for 2024 was 181.5 billion yen (a decrease of 62.4 billion yen or 25.6%).

With the decrease in operating income, net income attributable to owners of parent was 108.1 billion yen (a decrease of 50.4 billion yen or 31.8%).

For the full consolidated fiscal year, the U.S. dollar traded at 152 yen (a depreciation of 11 yen from the previous fiscal year) and the euro at 164 yen (a depreciation of 12 yen).

Forecast of Consolidated Business Results for the Fiscal Year Ending December 31, 2025

We expect emerging market motorcycle demand in the Land Mobility business to remain robust and for outboard motor demand in the Marine Products business to make a gradual recovery.

In terms of risks, we anticipate price hikes for aluminum and other raw materials as well as for labor and energy costs to continue going up. In response to these potential risks, we will work to reduce costs and improve productivity.

Furthermore, we will also be conducting structural reforms for the SPV and RV businesses in order to improve profitability, while with our core businesses, our efforts will be towards achieving sustainable growth by focusing on R&D, new product development, and upgrading our production equipment. The forecast consolidated business results for FY2025 are as follows:

Revenue: 2,700.0 billion yen (an increase of 123.8 billion yen or 4.8% from FY2024)

Operating Income: 230.0 billion yen (an increase of 48.5 billion yen or 26.7% from FY2024)

Net Income: 140.0 billion yen (an increase of 31.9 billion yen or 29.5% from FY2024)

Details: https://global.yamaha-motor.com/news/2025/0212/result.html

View source version on businesswire.com: https://www.businesswire.com/news/home/20250212964437/en/

Contacts

Please note: we only accept inquiries related to this release.

Corporate Communication Division
Global PR Team
Yamaha Motor Co., Ltd.
ymc_pr@yamaha-motor.co.jp

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 05:00:00 EEST | Press release

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and

Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 02:51:00 EEST | Press release

Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women’s health, the company’s portfolio includes more than 70 products across Women’s Health and General Medicines, which includes biosimila

PMC Organometallix Announces Price Increase on All Products25.4.2026 00:02:00 EEST | Press release

Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli

Frankfurt Higher Regional Court upholds BESREMi ® arbitral award in favor of AOP Health24.4.2026 19:52:00 EEST | Press release

Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into

Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 17:37:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards. “We are honored and grateful to be selected for the CNPV which is a clear validation of both the urgent unmet need facing millions of people living with treatment resistant depression and the innovative science of COMP360,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “As the most advan

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye